244 related articles for article (PubMed ID: 16140929)
1. Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers.
Liu H; Liu W; Wu Y; Zhou Y; Xue R; Luo C; Wang L; Zhao W; Jiang JD; Liu J
Cancer Res; 2005 Sep; 65(17):7635-43. PubMed ID: 16140929
[TBL] [Abstract][Full Text] [Related]
2. Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration.
Zhao W; Liu H; Liu W; Wu Y; Chen W; Jiang B; Zhou Y; Xue R; Luo C; Wang L; Jiang JD; Liu J
Int J Oncol; 2006 May; 28(5):1081-8. PubMed ID: 16596223
[TBL] [Abstract][Full Text] [Related]
3. The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-gamma (SNCG) in ovarian cancer.
Czekierdowski A; Czekierdowska S; Wielgos M; Smolen A; Kaminski P; Kotarski J
Neuro Endocrinol Lett; 2006 Jun; 27(3):381-6. PubMed ID: 16816827
[TBL] [Abstract][Full Text] [Related]
4. Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis.
Wu K; Quan Z; Weng Z; Li F; Zhang Y; Yao X; Chen Y; Budman D; Goldberg ID; Shi YE
Breast Cancer Res Treat; 2007 Mar; 101(3):259-67. PubMed ID: 16821081
[TBL] [Abstract][Full Text] [Related]
5. Cigarette smoke induces demethylation of prometastatic oncogene synuclein-gamma in lung cancer cells by downregulation of DNMT3B.
Liu H; Zhou Y; Boggs SE; Belinsky SA; Liu J
Oncogene; 2007 Aug; 26(40):5900-10. PubMed ID: 17369845
[TBL] [Abstract][Full Text] [Related]
6. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
[TBL] [Abstract][Full Text] [Related]
7. Stage-specific expression of breast cancer-specific gene gamma-synuclein.
Wu K; Weng Z; Tao Q; Lin G; Wu X; Qian H; Zhang Y; Ding X; Jiang Y; Shi YE
Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):920-5. PubMed ID: 14504205
[TBL] [Abstract][Full Text] [Related]
8. Synuclein gamma inhibits the mitotic checkpoint function and promotes chromosomal instability of breast cancer cells.
Inaba S; Li C; Shi YE; Song DQ; Jiang JD; Liu J
Breast Cancer Res Treat; 2005 Nov; 94(1):25-35. PubMed ID: 16142440
[TBL] [Abstract][Full Text] [Related]
9. Demethylation of the synuclein gamma gene CpG island in primary gastric cancers and gastric cancer cell lines.
Yanagawa N; Tamura G; Honda T; Endoh M; Nishizuka S; Motoyama T
Clin Cancer Res; 2004 Apr; 10(7):2447-51. PubMed ID: 15073123
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment.
Zhou Y; Inaba S; Liu J
Int J Oncol; 2006 Jul; 29(1):289-95. PubMed ID: 16773211
[TBL] [Abstract][Full Text] [Related]
11. Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas.
Wen XZ; Akiyama Y; Baylin SB; Yuasa Y
Oncogene; 2006 Apr; 25(18):2666-73. PubMed ID: 16314833
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms for aberrant expression of the human breast cancer specific gene 1 in breast cancer cells: control of transcription by DNA methylation and intronic sequences.
Lu A; Gupta A; Li C; Ahlborn TE; Ma Y; Shi EY; Liu J
Oncogene; 2001 Aug; 20(37):5173-85. PubMed ID: 11526506
[TBL] [Abstract][Full Text] [Related]
13. Synuclein-gamma targeting peptide inhibitor that enhances sensitivity of breast cancer cells to antimicrotubule drugs.
Singh VK; Zhou Y; Marsh JA; Uversky VN; Forman-Kay JD; Liu J; Jia Z
Cancer Res; 2007 Jan; 67(2):626-33. PubMed ID: 17234772
[TBL] [Abstract][Full Text] [Related]
14. Applications of novel monoclonal antibodies specific for synuclein-gamma in evaluating its levels in sera and cancer tissues from colorectal cancer patients.
Liu C; Guo J; Qu L; Bing D; Meng L; Wu J; Shou C
Cancer Lett; 2008 Sep; 269(1):148-58. PubMed ID: 18586385
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
Kelavkar UP; Harya NS; Hutzley J; Bacich DJ; Monzon FA; Chandran U; Dhir R; O'Keefe DS
Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):185-97. PubMed ID: 17164146
[TBL] [Abstract][Full Text] [Related]
16. Tumor cell-microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis.
Hu H; Sun L; Guo C; Liu Q; Zhou Z; Peng L; Pan J; Yu L; Lou J; Yang Z; Zhao P; Ran Y
Clin Cancer Res; 2009 Sep; 15(17):5485-93. PubMed ID: 19706805
[TBL] [Abstract][Full Text] [Related]
17. Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer.
Guo J; Shou C; Meng L; Jiang B; Dong B; Yao L; Xie Y; Zhang J; Chen Y; Budman DR; Shi YE
Int J Cancer; 2007 Sep; 121(6):1296-305. PubMed ID: 17534899
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional silencing of hedgehog-interacting protein by CpG hypermethylation and chromatic structure in human gastrointestinal cancer.
Taniguchi H; Yamamoto H; Akutsu N; Nosho K; Adachi Y; Imai K; Shinomura Y
J Pathol; 2007 Oct; 213(2):131-9. PubMed ID: 17724792
[TBL] [Abstract][Full Text] [Related]
19. Expression and promoter methylation of the RASSF1A gene in sporadic breast cancers in Chinese women.
Li Y; Wei Q; Cao F; Cao X
Oncol Rep; 2008 May; 19(5):1149-53. PubMed ID: 18425370
[TBL] [Abstract][Full Text] [Related]
20. Phospholipase C delta 1 is a novel 3p22.3 tumor suppressor involved in cytoskeleton organization, with its epigenetic silencing correlated with high-stage gastric cancer.
Hu XT; Zhang FB; Fan YC; Shu XS; Wong AH; Zhou W; Shi QL; Tang HM; Fu L; Guan XY; Rha SY; Tao Q; He C
Oncogene; 2009 Jul; 28(26):2466-75. PubMed ID: 19448674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
